 BEIJING, Aug. 11, 2021 GLOBE NEWSWIRE -- Genetron Holdings Limited Genetron Health or the Company, NASDAQ: GTH, a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that its Beijing clinical laboratory has received full marks under the National Center for Clinical Laboratories NCCL first nationwide, external quality assessment EQA of NGS-based comprehensive genomic profiling for solid tumors. The clinical laboratory passed the assessment with flying colors, earning the designation Outstanding Laboratory and receiving full marks, ranking first among all of the 63 laboratories that participated in the evaluation. 